Group 1 - The company MicroPort Robotics-B (02252) reported that as of the announcement date, the cumulative order volume for its core products in endoscopy, orthopedics, and vascular intervention exceeded 130 units [1] - The Tumi endoscopic surgical robot has achieved over 70 cumulative commercial orders globally, with nearly 20 new commercial orders signed in 2025, and the total installed base has surpassed 50 units [1] - Tumi has accelerated its clinical application, with over 10,000 human clinical surgeries performed globally to date [1] Group 2 - As of 2025, Tumi has received registration certification in over 10 countries or regions, with a total of more than 30 certified countries or regions worldwide [1] - The Tumi robot's clinical effectiveness, stability, safety, innovation level, and technological content have been increasingly recognized by international regulatory authorities [1] - The Honghu orthopedic surgical robot received registration approval from Health Canada in January 2025, expanding its presence in the global orthopedic surgical robot market [1] Group 3 - Following the global first registration approval for Tumi's remote surgery application in April 2025, the company continues to explore clinical applications in this field [2] - Tumi recently assisted Belgian surgeons in completing two remote surgeries, marking the first robot-assisted remote human surgeries in Europe [2] - The surgeries utilized a hospital's conventional network (V-LAN) with a bidirectional delay of only 20 milliseconds, ensuring the precision required for remote robotic surgery [2]
微创机器人-B(02252):集团旗下腔镜、骨科、血管介入核心产品的综合订单量累计超130台